by Pharmacy Times –
Investigational cell therapies are raising questions about whether treatment could influence the underlying course of chronic obstructive pulmonary disease (COPD), rather than provide short-term improvements alone. For a therapy designed to stimulate endogenous lung repair, the evidence would need to extend beyond an early change in symptoms or lung function to demonstrate durable clinical benefit.
Nebulized delivery introduces another question: Can a familiar respiratory device reliably administer a living-cell product? SMSbiotech is investigating Small Mobile Stem (SMS) cells, a proprietary, blood-derived cell population intended for allogeneic administration. The proposed mechanism involves interactions with cells involved in lung repair, but whether those interactions produce meaningful benefit in patients with COPD remains unestablished.
